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Abstract
Engineering T-cells to express receptors specific for antigens present on tumour tissue is
proving a highly effective treatment for some leukaemias. However, extending this to solid
tumours requires antigens that can be safely and effectively targeted. TEM8, a marker over-
expressed on the vasculature of some solid tumours, has been proposed as one such target.
A recent report stated that T-cells engineered to express a TEM8-specific chimeric antigen
receptor (CAR), when injected into mouse models of triple negative breast cancer, are both
safe and effective in controlling tumour growth. Here we report contrasting data with a panel
of TEM8-specific CAR-T-cells including one generated from the same antibody used in the
other study. We found that the CAR-T-cells demonstrated clear TEM8-specific cytotoxic and
cytokine release responses in vitro, but when injected into healthy C57BL6 and NSG mice
they rapidly and selectively disappeared from the circulation and in most cases caused rapid
toxicity. Infusing CAR-T-cells into a TEM8-knockout mouse indicated that selective loss of
cells from the circulation was due to targeting of TEM8 in healthy tissues. Histological analy-
sis of mice treated with a TEM8-specific CAR revealed evidence of inflammation in the lung
and spleen with large collections of infiltrating neutrophils. Therefore our data raise concerns
over potential on-target off-tumour toxicity with CARs targeting TEM8 and these should be
considered carefully before embarking upon clinical trials with such agents.
Introduction
Adoptive therapy using tumour-specific T-cells can be a very effective treatment for human
cancer, but naturally occurring T-cells with the appropriate tumour specificity are rare. There-
fore more recent work has employed genetic engineering techniques to rapidly and reliably
introduce genes encoding receptors specific for defined tumour antigens[1]. This includes
engineering T-cells to induce expression of a chimeric antigen receptor (CAR), which gener-
ally combines the antigen-binding domains of an antibody in the form of a single chain vari-
able fragment (scFv) linked to the signalling domain (CD3z chain) from the T-cell receptor
complex. Such CARs based on an antibody specific for the B cell marker CD19 have proven
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highly effective in treating some leukaemias[2–4], leading to recent FDA approval for some of
these therapies. Unsurprisingly, these CD19-specific CARs mediate so called “on-target, off-
tumour” effects since the target antigen is also expressed on healthy B cells leading to B-cell
aplasia and hypogammaglobulinaemia, but this can be managed clinically by regular infusions
with immunoglobulin.
Given the clinical success of CAR T-cell therapy for leukaemias, there is considerable inter-
est in extending its use to the more common solid tumours. However, this is proving more
challenging, partly because of the hostile tumour microenvironment that can include multiple
immune evasion mechanisms but also because of the lack of suitable target antigens. Targeting
the tumour stroma such as the tumour vasculature, rather than the malignant cells directly, is
an attractive alternative approach since it is readily accessed by circulating T-cells and is less
genetically unstable than malignant cells[5], reducing the likelihood of antigen-loss variants
[6]. Furthermore, targeting the tumour vasculature should not only damage the surrounding
tumour tissue but also malignant tissue downstream of that vessel. This approach again
requires the identification of specific antigens, and a growing list of tumour endothelial mark-
ers (TEMs) have been described.
TEM8 was originally identified as a TEM in colorectal carcinoma[7] and although it is
expressed in the endothelial cells of developing mouse embryos[8], it was not detectable in
healthy tissues of adult mice[9]. Equally, studies in human tissues failed to detect it during
physiological angiogenesis required for corpus luteum development and wound healing[7].
TEM8 is a single-pass cell surface glycoprotein 564 amino acids long, with a von Willebrand
factor type A (vWA) domain in its extracellular region[10]. It is highly conserved with 96%
amino acid sequence identity between mouse and man[8]. TEM8 binds collagen and promotes
endothelial cell migration in vitro and is thereby thought to play an important role in angio-
genesis[11, 12]. TEM8 also acts as a receptor for anthrax toxin[13], and is known as anthrax
toxin receptor 1 (ANTXR1).
In addition to colorectal cancer, TEM8 is upregulated on vessels in various human and
mouse tumour types[8, 11, 14], and in some cases is also expressed by the malignant cells[8,
15, 16]. Its importance in cancer has been demonstrated using TEM8 knockout mice that
show impaired tumour growth[9, 17]. Furthermore, targeting this molecule in mice using
TEM8 vaccines[18, 19], an anti-TEM8/truncated tissue factor fusion protein[14] and sublethal
doses of anthrax toxin[20] can inhibit angiogenesis and tumour growth, as well as prolong
survival. In 2012, a study using antibody phage display reported the generation of five TEM8-
specific human antibodies (L1, L2, L3, L5 and 1D2) which inhibited tumour-induced angio-
genesis as well as cancer growth in several mouse tumour models[9]. More recently, the safety
and therapeutic potential of a TEM8-specific CAR based on the L2 antibody was explored
using mouse models of triple negative breast cancer[21]. These studies showed that not only
could infusion of these L2 CAR T-cells inhibit tumour growth, but there were no toxic effects
reported.
Here we present contrasting findings using a panel of TEM8-specific CARs based on the
same antibodies. Some of these, including L2, caused significant toxicity in healthy mice,
apparently through targeting of TEM8 in healthy tissue, thus raising concerns over the use of
such CARs for human studies.
Results
Generation and expression of TEM8-specific CARs
The gene sequences encoding scFv domains based on the TEM8-specific human antibodies
L1, L2, L3, L5 and 1D2 were cloned into retroviral vectors to encode second generation CARs
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with a CD28 costimulatory domain upstream of the CD3z chain as illustrated in Fig 1A. In
addition, the CAR gene was separated from a truncated CD34 marker gene by a foot-and-
mouth disease virus 2A peptide linker, ensuring equimolar expression of both genes. In this
way CD34 expression could be used as a marker for CAR expression. Following transduction
of human T-cells using these retroviral vectors, the CD34 marker gene was clearly detectable
by flow cytometry for all five CAR constructs, indicating that all five CARs are readily
expressed (Fig 1B).
In vitro testing of TEM8-specific CAR T-cells
To explore the function of human T-cells expressing the five different CARs, they were co-cul-
tured with the LS174T tumour cell line which is naturally TEM8-negative[9] but which we
engineered to stably express the mouse form of TEM8 (S1 Fig). As shown in Fig 2A, when test-
ing for secretion of interferon-gamma (IFN-gamma), T-cells expressing four out of the five
CARs specifically responded to the TEM8-expressing LS174T cells, with the strongest
responses seen with L1 and L2 CARs. The only CAR that failed to show a clear response was
that based on the 1D2 antibody. Further studies explored the cytotoxic activity of the different
CAR T-cells using the same target cells and showed a similar pattern of response, with the
highest levels of cytotoxicity seen with L1, L2 and L3 CARs, but no specific cytotoxicity with
Fig 1. Generation and expression of CAR constructs in T-cells. (A) Schematic representation of recombinant
retroviral vectors encoding TEM8-specific CARs. Recombinant retroviral vectors coexpressed a truncated human
CD34 marker and an scFv fragment from one of 5 different TEM8-specific monoclonal antibodies linked to a CD28
costimulatory domain and a CD3 zeta chain. The 2A peptide linker ensured equimolar expression of both gene
constructs. (B) Expression of all 5 TEM8-specific CARs (based on monoclonal antibodies L1, L2, L3, L5 and 1D2) in T
cells was demonstrated by flow cytometry staining for the coexpressed CD34 marker. % values show proportion of
cells stained for CD34 in transduced T cells (black line) compared to mock-transduced T cells (shaded).
https://doi.org/10.1371/journal.pone.0224015.g001
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the 1D2 CAR (Fig 2B). Using recombinant human and mouse TEM8 proteins, titration studies
showed that the CAR T-cell response (measured by secretion of IFNγ) was strongest with L1
and L2 CARs, and somewhat weaker responses seen with L3 and L5 CARs. However, although
the 1D2 CAR showed low but detectable responses to the human TEM8 protein when tested at
Fig 2. CAR T cell responses to mouse and human TEM8. Human T cells engineered to express TEM8-specific CARs (L1, L2, L3, L5, 1D2) or mock-
transduced T cell controls were tested for response to LS174T cells engineered to express full-length mouse TEM8. Antigen specific responses were
detected using (A) IFN-gamma ELISA and (B) cytotoxicity assay (tested at effector:target (E:T) ratios of 10:1 and 5:1). (C) Responses to titrated
concentrations of recombinant human and mouse TEM8 protein were assessed by IFN gamma release. In all cases CAR-T cell lines were diluted with
mock T cells to equalise for transduction efficiency. Graphs show the mean of triplicate cultures (± standard deviation, SD) and are each representative
of 3 experiments.
https://doi.org/10.1371/journal.pone.0224015.g002
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higher concentrations, there was no detectable response to the mouse protein (Fig 2C). These
results compare well with the binding affinities of these antibodies, since the affinities of L1,
L2, L3 and L5 for human and mouse TEM8 are all within the range of 0.18–0.36nM. In con-
trast, the affinity of 1D2 for human TEM8 is only 7.6nM, and for mouse TEM8 it is 31.2nM,
approximately 100 times lower than each of the other four antibodies[9]. Data demonstrating
the expression and antigen-specific function of these CARs in mouse T-cells are shown in S2
Fig.
In vivo testing of TEM8-specific CAR T-cells
Having demonstrated TEM8-specific function for four of the CARs, we then began a series of
small toxicity studies in healthy mice. In the first experiment, C57BL/6 mice were treated with
a single intravenous infusion of 20 million total T-cells derived from a congenic (CD45.1+)
mouse strain with 55%, 64%, 40% or 55% of these cells expressing the L1, L2, L3 or L5 CARs
respectively. Not only were mice monitored closely for signs of toxicity, but the persistence of
the infused CAR T-cells was also monitored by serial tail bleeds using the CD34 marker as an
indicator of CAR expression and CD45.1 as a marker of the infused T-cell population. After
24hrs, mice injected with the L2 and L3 CAR showed signs of toxicity with a hunched posture,
piloerection and greatly reduced levels of activity which necessitated culling of the animals.
The remaining mice treated with L1 and L5 CARs did not show such signs, but tail bleeds indi-
cated that although more than half of the infused T-cells initially expressed the CAR, within 3
days post-infusion nearly all of the L1 and L5 CAR-expressing cells were no longer detectable
in the circulation. In contrast, infused T-cells that did not express the CAR (i.e. CD34-
CD45.1+) were clearly detectable and represented 35–42% of the total circulating T-cell pool at
3 and 7 days post infusion. The selective loss of CAR-expressing T-cells continued until day 28
when the experiment was ended (Fig 3A).
In the second in vivo experiment, congenic mouse T-cells expressing the L1 or L5 CARs
were again tested in healthy C57BL/6 mice but this time we also tested the 1D2 CAR, and T-
cells expressing a control CAR that lacked a scFv domain (no scFv) and therefore should not
target an antigen. Mice were infused with 20 million total T-cells of which 81%, 70%, 84% and
77% expressed the L1, L5, 1D2 and no scFv CARs respectively. None of the mice showed signs
of overt toxicity, but all mice treated with the L1 and L5 CARs again showed rapid and selec-
tive depletion of the CAR expressing T-cells such that these cells became almost undetectable
from day 9 (Fig 3B). In contrast, T-cells infused into these L1 and L5-treated mice that did not
express the CAR (i.e. CD34- CD45.1+) were again clearly detectable and represented >35% of
the total circulating T-cell pool. Mice treated with T-cells expressing the no scFv control CAR
showed an initial drop in the percentage of infused cells expressing this CAR, but this stabilised
4 days post-infusion and remained at ~50% for the next 17 days. 1D2 CAR T-cells were selec-
tively depleted during the first week but then remained at ~20% for the rest of the experiment.
The third in vivo experiment used human T-cells injected into healthy immunocompro-
mised NSG mice. Three mice received 20 million total T-cells of which 21% expressed the L2
CAR and again within 24hrs they all showed the same signs of toxicity seen in the first in vivo
experiment, which necessitated culling of the animals. In contrast, mice (n = 3 per group)
treated with 20 million total human T-cells expressing the 1D2 CAR or the no scFv CAR con-
trol showed no signs of toxicity even when infused again on day 5 and day 9 with the same
cells. Note 1D2 and no scFv CARs were expressed on 25% and 22% of the infused T cells
respectively. Tail bleed analysis again showed that the 1D2 CAR T-cells persisted in the circula-
tion to the same extent as the no scFv control CAR (Fig 3C). The fourth in vivo experiment
largely repeated the third although L2 and no scFv CARs were expressed on 56% and 63% of
TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo
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Fig 3. TEM8-specific CAR T cells are selectively lost from the circulation in healthy mice. (A) Mouse T cells engineered to express TEM8-specific CARs (L1,
55% transduced; L2, 64% transduced; L3, 40% transduced; L5, 55% transduced) or mock-transduced T cell controls were injected (20 million total T cells/mouse)
into single healthy C57BL/6 mice and persistence measured by sequential tail bleeds. Note mice treated with L2 and L3 CARs are not shown as they had to be culled
TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo
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20 million total infused T-cells respectively, and 1D2 CAR was not tested. Toxicity was again
observed in all three L2 CAR-treated mice (hunched posture, piloerection and greatly reduced
levels of activity) this time 3 days post infusion. In contrast, mice treated with the control (no
scFv) CAR showed no toxicity. Three days post infusion, mice were analysed for persistence of
infused cells and again there was clear evidence for selective loss of TEM8-specific CAR T-cells
from the peripheral blood (Fig 3D). The L2 CAR-treated mice in this fourth in vivo experi-
ment also showed a clear loss in body weight whereas no such change was seen in control (no
scFv) CAR treated mice (Fig 3E). Three days post infusion all mice in this fourth experiment
were culled and tissues taken for histological analysis. Haematoxylin and eosin stained sections
were analysed by an experienced pathologist who was unaware of the treatment received by
each mouse. Brain, colon, liver, kidney, pancreas, and heart tissues showed no pathology in
either group of mice, but lung and spleen tissues showed evidence of inflammation in all L2
CAR treated animals, with numerous neutrophils present both in the red pulp of the spleen
and surrounding the blood vessels and bronchioles in the lung. In contrast, there was no infil-
tration of neutrophils in the lung or spleen tissues of any mice treated with the control (no
scFv) CAR (Fig 4 and S3 Fig).
Finally, to explore whether these effects were dependent on TEM8 expression, we used a
TEM8 knockout mouse. Mouse T-cells from a congenic strain were engineered to express the
L2 TEM8-specific CAR or a control (no scFv) CAR and injected intravenously into healthy
wild type and TEM8 knockout C57BL/6 mice. On this occasion, the L2 CAR T-cells did not
mediate a toxic reaction even though the number of infused T-cells that expressed the CAR
was similar to previous experiments. Nevertheless, these CAR T cells were again selectively lost
from the circulation in wild type mice as had been observed with all the high affinity TEM8--
specific CARs in the mouse experiments described above. Importantly, however, L2 CAR T-
cells persisted in the circulation of TEM8 knockout mice. The control CAR T-cells persisted in
the circulation of both mouse strains. Thus selective loss of L2 CARs from the circulation was
TEM8-dependent (Fig 5).
Discussion
Studying a panel of CARs specific for the tumour endothelial marker TEM8, we identified sig-
nificant toxicity when some of them were tested in healthy mice. Furthermore, we also demon-
strated selective and rapid depletion of all high avidity TEM8-specific CAR T-cells from the
circulation. This suggested the CARs were targeting TEM8 or cross-reacting with another anti-
gen expressed on healthy tissue(s) which resulted in toxicity and/or migration of the CAR T-
cells out of the bloodstream and into the target tissue(s). Histological analysis of TEM8-specific
CAR T-cell-treated mice also revealed evidence of inflammation in lung and spleen tissue.
Studies using a TEM8 knockout mouse subsequently showed that selective loss of the CAR T-
cells from the circulation was TEM8 dependent, strongly suggesting that the CAR T-cells are
recognising TEM8 expressed on healthy tissue(s). Thus, despite elevated levels of TEM8
within 24hrs post treatment. (B) Mouse T cells engineered to express TEM8-specific CARs (L1, 81% transduced; L5, 70% transduced; 1D2, 84% transduced) or a
control CAR (no scFv, 77% transduced) were injected (20 million total T cells/mouse) into healthy C57BL/6 mice (n = 2 per group) and persistence measured by
sequential tail bleeds. (C) Human T cells engineered to express TEM8-specific CARs (L2, 21% transduced; 1D2, 25% transduced) or a control CAR (no scFv, 22%
transduced) were injected (20 million total T cells/mouse) into healthy NSG mice (n = 3 per group) on 3 occasions (indicated with black arrowheads) and
persistence measured by sequential tail bleeds. Note mice treated with L2 CARs are not shown as they had to be culled 24hrs post treatment. (D) Human T cells
engineered to express TEM8-specific CARs (L2, 55.6% transduced) or a control CAR (no scFv, 63% transduced) were injected (20 million total T cells/mouse) into
healthy NSG mice (n = 3 per group) and persistence measured by tail bleeds. Changes in body weight of these mice are shown in (E). Graphs A-D show CAR T cells
(CD34+) as a percentage of the total infused T cell population. Results shown in B are the mean of duplicate values and results shown in C, D and E are the mean of
triplicate values (± SD).
https://doi.org/10.1371/journal.pone.0224015.g003
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expression in tumour tissues, levels on healthy tissues can still be sufficient to be targeted by a
potent agent such as a high avidity multivalent CAR T-cell.
This finding is particularly significant given a recent publication demonstrating safety and
anti-tumour efficacy in a mouse model of triple negative breast cancer using a CAR based on
the same L2 antibody that mediated toxicity in 7/11 wild type mice in our studies[21]. Reasons
for these contradictory findings could lie in subtle changes in the design of the CAR. For exam-
ple, different retroviral vectors may have led to different levels of CAR expression per cell.
Also, the scFv domain in our study comprised the heavy chain antibody sequence followed by
the light chain, whereas in the other study the genes encoding these antibody chains were in
reverse order. Equally, the other study tested two versions of L2 CAR that included a costimu-
latory region from CD28 with or without an additional costimulatory domain from 4-1BB.
Most of their in vivo studies focused on the second CAR and showed no toxicity using doses of
up to 10 million cells (70% transduced). Nevertheless, no toxicity was reported when the CAR
with the CD28 domain alone was injected intratumourally at a dose of 25 million cells/mouse.
Whatever the reasons for the lack of toxicity in this other study, our results demonstrating tox-
icity with an L2 CAR even at doses of 4 million CAR-expressing T-cells per mouse, combined
with evidence for TEM8-mediated selective loss of high avidity CAR T-cells from the circula-
tion of healthy mice, highlights the risk of on-target, off-tumour effects should a TEM8-speci-
fic CAR, especially one based on the L2 antibody, be tested in patients. This is of particular
concern if strategies are employed to enhance the anti-tumour effects of the CAR, for example
through dose escalation or increasing the levels of CAR expression and/or function. In support
of our findings, it should be noted that toxicity was also reported when the L2 antibody was
Fig 4. Histological analysis of mice treated with TEM8-specific or control CAR T-cells. Representative images of
haematoxylin and eosin stained lung and spleen tissues from the fourth in vivo experiment where NSG mice were
treated with human T cells engineered to express TEM8-specific CARs (L2) or a control CAR (no scFv). Mice (n = 3
per group) were injected with 20 million total T cells/mouse of which 11.1 million and 12.6 million expressed the L2
and no scFv CARs respectively. Tissues were taken 3 days later and showed evidence of neutrophil infiltration in all L2
CAR treated mice but none of the control CAR treated mice. (Magnification = x400).
https://doi.org/10.1371/journal.pone.0224015.g004
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Fig 5. Persistence of TEM8-specific CAR T cells in the circulation of healthy wild type and TEM8 knockout mice.
Mouse T cells from a congenic strain were engineered to express the L2 TEM8-specific CAR or a control CAR (no
scFv) lacking the scFv antigen-binding domain. T cells were injected intravenously into wild type (black bars) or
TEM8 knockout mice (white bars) and tail bleeds sampled to identify the infused cells (CD45.1+) that expressed the
CAR (CD34+). Graphs show the results of two separate experiments where tail bleeds were analysed (A) 8 days and (B)
6 days post infusion. All experiments used two mice per group (except where indicated). T cells engineered for these
experiments were>50% transduced, and for data shown in (A) and (B) the number of infused T cells per mouse that
actually expressed a CAR was 5 million and 12 million respectively. Data represent the mean percentage (+ SD) of
infused cells that expressed a CAR.
https://doi.org/10.1371/journal.pone.0224015.g005
TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo
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used to engineer mouse T-cells to express a secretable bi-specific T-cell engager. This engager
used a TEM8-specific scFv from the L2 antibody linked to a scFv recognizing CD3. Intrave-
nous injection of 10 million of these T-cells resulted in death of 7/10 mice[22].
To reduce the risk of on-target, off-tumour toxicity with such CARs, one possibility is to
use them in a combinatorial approach, where T-cells are engineered to express two distinct recep-
tors, and activation is dependent on encountering both target antigens which are only co-
expressed in tumour tissues[23, 24]. Use of RNA transfection of T-cells for transient expression of
the CAR[25] or use of suicide gene strategies[26] can also limit the risks, or better still a “tunable”
system where CAR expression levels can be regulated through administration of a drug[27]. Alter-
natively, reducing the affinity of the TEM8-specific CAR might permit discrimination between
levels of the target antigen expressed at the tumour site and levels expressed in healthy tissues as
has been shown for other CARs[28, 29]. In this regard it is interesting to note that although the
1D2 TEM8-specific antibody has a 100-fold lower affinity than L2 for mouse TEM8[9], and
according to our data T-cells expressing a 1D2 CAR do not respond to the mouse protein, this
antibody has intermediate affinity for human TEM8. Preclinical safety and efficacy testing of a
1D2 CAR in a mouse model would, however, require generation of a human TEM8 knockin.
Methods
Generating human and mouse CAR T cells
The gene sequences encoding each of the TEM8-specific human antibodies L1, L2, L3, L5 and
1D2 were kindly provided by B. St Croix (National Cancer Institute, Frederick, MD) and used
to design synthetic DNA sequences (GenScript) encoding an scFv region and then cloned into
the CAR vector pMP71.tCD34.2A.CD19.IEVz[30] as a ClaI, NotI fragment, replacing the
CD19-specific scFv region. These vectors were originally constructed using the MP71 retrovi-
ral expression plasmid (a kind gift from C. Baum, Hannover) and co-expressed a truncated
human CD34 marker gene[31]. The gene sequences of all new constructs were verified.
To generate recombinant retrovirus for transducing mouse T cells, Phoenix ecotropic pack-
aging cells were transfected with the appropriate MP71 retroviral expression vector encoding
the CAR and pCL eco (Imgenex) using FuGENE HD (Roche) according to the manufacturer’s
instructions. Recombinant retrovirus for transducing human T cells was generated in the
same way but using Phoenix amphotropic packaging cells and pCL ampho. Transduction of
mouse T cells was conducted using mouse splenocytes pre-activated for 48 hours with conca-
navalin A (2μg/ml; Sigma) and mouse interleukin-7 (1ng/ml; eBioscience) in RPMI 1640
(Sigma) containing 10% foetal bovine serum (FBS; PAA, Pasching Austria), 2mM L-gluta-
mine, 100 IU/ml penicillin, and 100ug/ml streptomycin (standard medium). For human T
cells, peripheral blood mononuclear cells (PBMCs) were isolated from aphereses cones[32]
collected from healthy adult volunteers (male or female, aged>18 years) who attended the
National Blood Donor Centre, Birmingham. PBMCs were isolated by density gradient centri-
fugation on Lymphoprep (Axis Shield, Oslo, Norway). They were then pre-activated for 48
hours using anti-CD3 antibody (30ng/ml; OKT3 eBioscience), anti-CD28 antibody (30ng/ml;
37407 R&D Systems) and interleukin-2 (IL2, 300 U/ml; Chiron, Emeryville, CA) in standard
medium containing 1% human AB serum (TCS Biosciences, Buckingham, UK). Pre-activated
human and mouse T cells were subsequently transduced (or mock-transduced with condi-
tioned supernatant from non-transfected Phoenix cells) by spinfection in retronectin
(Takara)-coated plates according to the manufacturer’s instructions. After spinfection, mouse
T cells were cultured for 24hrs in standard medium with IL2 (100 U/ml), then purified using
Ficoll-Paque premium 1.084 (GE Healthcare). Human T cells were cultured in standard
medium plus 1% human AB serum with IL2 (100 U/ml).
TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo
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Cell lines
LS174T cells[33] were obtained from ATCC and cultured in DMEM containing 10% FBS,
2mM L-glutamine, 100 IU/ml penicillin, and 100μg/mL streptomycin. Stable expression of
mouse TEM8 within these cells was achieved by transduction using the lentiviral plasmids
psPAX2 (lentiviral packaging; Addgene, Cambridge, MA, USA), pMD2G (envelope plasmid;
Addgene) and pWPI lentiviral mammalian expression plasmid (Addgene) into which we had
cloned the mouse TEM8 gene following digestion using PacI and PmeI restriction enzymes
(New England BioLabs, MA). Plasmids were transfected into 293T cells (from ATCC) using
FuGENE 6 according to the manufacturer’s instructions in a ratio of 1:2.5:3.3 for pMD2G:
psPAX2:pWPI. LS174T cells were then transduced with lentivirus-containing culture superna-
tant mixed with polybrene (8μg/ml, Merck, Millipore). Cell lines were screened for myco-
plasma using MycoAlert detection kit (Lonza, Basel).
Recombinant TEM8
Genes encoding the human or mouse forms of TEM8 fused to the human Fc protein were
cloned into the pFUSE-mIgG2A-Fc1 vector (InvivoGen, San Diego, CA). TEM8 protein pro-
duction was then carried out with the help of the Protein Expression Facility, University of Bir-
mingham. Human TEM8-Fc/pFUSE-mIgG2A or mouse TEM8-Fc/pFUSE-mIgG2A plasmids
were transfected into 293T cells using polyethylenimine (PEI 25000; Polysciences, Warrington,
PA) in Opti-MEM Reduced Serum Medium (Gibco) and 7 days later supernatants were har-
vested and protein purified using Protein A Sepharose CL-4B (GE Healthcare) according to
the manufacturer’s instructions.
IFNγ ELISA
LS174T cells (2x104/well) were co-cultured in triplicate with human CAR T-cells (2x105/well)
in 96-well flat bottom plates. Alternatively CAR T-cells (2x105/well) were incubated in wells
pre-coated for 4 hours with recombinant TEM8-Fc protein (or Fc protein alone) at concentra-
tions indicated. Cells were incubated at 37˚C/5% CO2 in 100μl/well of RPMI supplemented
with 10% FBS, 2mM L-glutamine, 100 IU/ml penicillin, and 100ug/ml streptomycin and IL2
(25 U/ml). After 18 hours, culture supernatant was tested for secreted IFN-gamma using an
ELISA (Pierce Endogen, Rockford, IL) according to the manufacturer’s instructions.
Cytotoxicity assay
Chromium release assays have been described in detail previously[34]. They were set up at
known effector:target ratios (1250 targets/well) and harvested after 7.5 hours.
In vivo studies
Mice were housed in individually ventilated containers with a 12 hour day/night light cycle at
temperatures of 21 +/- 2˚C and relative humidity of 55% +/- 5%. All mice were allowed free
access to water and a maintenance diet (EURodent diet 14%). All cages contained wood shav-
ings, bedding material and a plastic house. Six to eight week old female C57BL/6 mice (Charles
River Laboratories) or TEM8-knockout mice[17] (a kind gift from B. St Croix, National Can-
cer Institute, Frederick, MD) received non-myeloablative (5 Gy) total body irradiation (TBI)
and 18 hours later CAR- or mock-transduced T-cells from CD45.1+ congenic BoyJ mice
(Charles River Laboratories) were injected into the tail vein. Six to eight week old female NSG
mice (Charles River Laboratories) were injected into the tail vein on up to 3 occasions with 20
million CAR- or mock-transduced human T-cells at the times and doses indicated. All mice
TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo
PLOS ONE | https://doi.org/10.1371/journal.pone.0224015 October 17, 2019 11 / 15
were monitored every 15 minutes for the first hour post infusion, and then at least once daily
for signs of toxicity. Humane endpoints included >20% body weight loss, hunched posture,
continued piloerection and/or inactivity for a period of 24hrs or dyspnoea. Once humane end-
points were reached they were culled immediately (note no animals died before meeting the
humane endpoint criteria). Mice were assessed for toxicity by experienced animal workers and
to avoid subjective bias they were blinded to the treatment group to which the animal had
been assigned. Immune monitoring was conducted with serial tail bleeds. When staining T
cells from heparinized tail bleeds they were first subjected to red blood cell lysis using BD
Pharm Lyse (Becton Dickinson). They were then washed with PBS and stained with Live/Dead
Fixable Violet Dead Cell Stain Kit (Life Technologies) for 20 mins in the dark, then washed
with flow buffer (0.5% w/v BSA + 2mM EDTA in PBS; pH7.2). If staining for infused mouse
T-cells, they were then stained with anti-mouse CD4-PE (clone H129.19), CD8-FITC (clone
53–6.7) and CD45.1-PE-Cy7 (clone A20) (all from BD Biosciences) for 30mins on ice in the
dark. Alternatively when analysing infused human T-cells, they were stained with anti-human
CD4-FITC (clone RPA-T4, BD Biosciences) and anti-human CD8-PE (clone RPA-T8,
eBioscience). In all cases CAR-expressing cells were identified by co-staining with anti-human
CD34-APC (clone 561, BioLegend). Cells were analysed using a BD LSR II flow cytometer and
FlowJo software (TreeStar Inc, Ashland, OR). Histological analysis was conducted on forma-
lin-fixed tissue stained with haematoxylin and eosin. Tissues were analysed using an Olympus
SC100 microscope with Olympus cellSens Standard software.
Study approval
Studies with human donors were approved by the National Research Ethics Service Committee
West Midlands (Solihull, UK). All donors were adults and gave written informed consent. All
mouse studies were performed under UK Home Office authorisation and all animal workers
were fully trained and held personal licenses granted by the UK Home Office.
Supporting information
S1 Fig. Mouse TEM8 expression in engineered LS174T cells. LS174T cells transduced with a
lentivirus expressing the murine form of TEM8 were stained with the TEM8 specific L2 mono-
clonal antibody (80ug/ml) or a concentration- and isotype-matched antibody control (clone
ZX4, Thermo Fisher Scientific). They were then stained with a phycoerythrin-conjugated goat
anti-mouse IgG antibody (Biorad) and analysed by flow cytometry using an LSRII Cytometer
(Becton Dickinson) and FlowJo software (Tree Star).
(TIF)
S2 Fig. CAR expression and function in engineered mouse T-cells. (A) Expression of all 5
TEM8-specific CARs (L1, L2, L3, L5 and 1D2) and the no scFv control CAR in mouse T cells
was demonstrated by flow cytometry staining for the coexpressed CD34 marker. % values
show proportion of cells stained for CD34 in transduced T cells (black line) compared to
mock-transduced T cells (shaded). (B) Antigen specific responses to LS174T cells expressing
mouse TEM8 were detected using a mouse IFN-gamma ELISA platinum kit (Invitrogen).
CAR-T cell lines were diluted with mock-transduced T cells to equalise for transduction effi-
ciency. The graph shows the mean of duplicate cultures (± standard deviation, SD).
(TIF)
S3 Fig. Representative images of haematoxylin and eosin stained tissues from the fourth in
vivo experiment where NSG mice were treated with human T cells engineered to express
TEM8-specific CARs (L2) or a control CAR (no scFv). Mice (n = 3 per group) were injected
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with an effective dose of 11.1 million or 12.6 million T cells that all expressed the L2 or no scFv
CAR respectively. Tissues were taken 3 days later. (Magnification = x200).
(TIF)
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